Product Description
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Colorectal Cancer|Kidney Diseases|Melanoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT03239145 | P1 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Colorectal Cancer|Ovarian Cancer|Melanoma|Kidney Diseases |
2025-02-28 |